Current and future imaging techniques and recurrent prostate cancer

An article just reproduced on the Medscape Oncology web site provides a very readable review of what the authors describe as, “A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer”. … READ MORE …

What’s being presented at the AUA in May: Part V

Eight papers on prostate cancer are being presented in the major plenary sessions at the annual meeting of the American Urological Association this year. All eight papers are interesting, but only the ones by Lin et al. and by Karnes et al. seem to hold potential for being of practice-changing significance. … READ MORE …

What’s being presented at the AUA in May: Part IV

There are numerous sessions at the annual meeting of the American Urological Association that focus on basic research and technical topics. A few of our readers may be interested in a very few of these presentations and posters, but the vast majority of these presentations and posters are about very early stage scientific research. … READ MORE …

What’s being presented at the AUA in May: Part I

This is the first of several summary posts commenting briefly on new data to be presented at the annual meeting of the American Urological Association (AUA) this year. Individual presentations of important new data will be separately addressed … READ MORE …

AUA abstracts now accessible on line

As suggested in a post yesterday, the abstracts accepted for presentation at the annual meeting of the American Urological Association (AUA) are now all accessible and searchable on line.

Abstracts of papers to be presented at AUA annual meeting

For those who are interested in doing their own “hunting” for new data being presented at the upcoming meeting of the American Urological Association (in May), the abstracts of papers to be presented at that meeting are now available on line in the Journal of Urology, and should soon be openly available in a searchable format on the meeting web site. … READ MORE …

A message from the National Association for Proton Therapy

According to a media release issued yesterday by the National Association for Proton Therapy (NAPT), “Approximately 97 percent of patients who received only an advanced form of radiation called proton therapy for prostate cancer report that they have not experienced a recurrence of their disease.” … READ MORE …

Bill Manning’s blog: Part III

Here is the third of Bill’s blog posts. He, and we, hope it will be helpful to all those battling late stage prostate cancer as he takes advantage of some of the new drugs that have come to market over the past couple of years. Click here for earlier parts if you missed them. … READ MORE …

Neuroendocrine prostate cancer and MLN8237 (alisertib)

Neuroendocrine prostate cancer or NEPC is an aggressive, late stage form of castration-resistant prostate cancer (CRPC) with a very poor prognosis. Most patients will live for less than 12 months after diagnosis with NEPC. … READ MORE …

Does widespread PSA testing lower risk for prostate cancer-specific mortality?

The question of whether widespread testing/screening for risk of prostate cancer really does, on its own, lower risk for metastatic disease and prostate cancer-specific mortality is not yet resolved … however much one might want it to be! … READ MORE …

Dr. Laurence Klotz talks active surveillance on Cure Panel Talk Show

The most recent Cure Panel Talk Show on Prostate Cancer, featuring Dr. Laurence Klotz of Sunnybrook Cancer Center and the University of Toronto in Toronto, Canada, is now available on line. … READ MORE …

Second approved indication for enzalutamide later this year?

Astellas Pharma and Medivation have submitted all relevant data to the US Food & Drug Administration (FDA) in support of their application for approval of enzalutamide (Xtandi) for the treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (CRPC). … READ MORE …

Mayo Clinic unveils new proton beam radiotherapy center

Yesterday the Mayo Clinic in Rochester, MN, unveiled the building in which its new proton beam radiation therapy (PBRT) unit will be situated. However, it is clear from the article in the Minneapolis Star-Tribune that the value and the cost-effectiveness of PBRT is still a major issue for many. It is not yet clear when the Mayo Clinic expects to start treating patients with PBRT.

A “state-of the art” update on prostate cancer management

The March issue of The ASCO Post, just out this morning, includes a brief article based on conversations by Dr. Richard Boxer with Dr. Peter Scardino (of Memorial Sloan-Kettering Cancer Center in New York) and Dr. Howard Sandler (of Cedars-Sinai Medical Center in Los Angeles) held at the Gentourinary Cancers Symposium. … READ MORE …

The toxicity of SBRT in treatment of prostate cancer, redux …

In another new article published this week, a group of clinical researchers at Georgetown University have reported their experience of patient-reported outcomes data at up to 2 years after first-line therapy with stereotactic body radiation therapy (SBRT). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,073 other followers